Study of BV100's effect on polymyxin B in healthy volunteers
Treatments studied
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Have healthy kidney function (eGFR greater than 60)
- Have a BMI between 19.0 and 30.0 (healthy weight range)
- No allergy or sensitivity to polymyxin B, colistin, or rifabutin-type antibiotics
- No history of serious allergic reactions, drug allergies, or antibiotic-related diarrhea in the past year
- Healthy heart rhythm and blood pressure (checked at screening)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibiotic (called VRP-034) that is similar to a standard antibiotic used for serious infections. It is being compared to the standard version to see if it is safe, how the body processes it, and how it affects the kidneys, in healthy people.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This study tests an experimental antibiotic called BWC0977 to see if it is safe and well-tolerated when given as single and multiple doses. It is for healthy volunteers to understand how the drug behaves in the body before moving to patient trials.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study tests a new investigational drug (BMS-986521) in healthy volunteers to see how safe it is and how the body processes it. It helps researchers decide if the drug can be tested in future studies.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.